An Open-Label, Multicenter, Follow-up Study to Evaluate the Long-Term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment in Subjects ≥16 Years of Age With Partial Seizures With or Without Secondary Generalization
Latest Information Update: 12 Aug 2024
At a glance
- Drugs Brivaracetam (Primary)
- Indications Partial epilepsies
- Focus Adverse reactions; Registrational
- Sponsors UCB Biopharma; UCB Japan
- 11 Apr 2023 Planned number of patients changed from 227 to 217.
- 27 Jun 2022 Planned End Date changed from 1 Mar 2025 to 3 Mar 2025.
- 27 Jun 2022 Planned primary completion date changed from 1 Mar 2025 to 3 Mar 2025.